Frontiers in Immunology (Feb 2021)

Tenascin-W Is a Novel Stromal Marker in Biliary Tract Cancers

  • Ismaïl Hendaoui,
  • Ahlem Lahmar,
  • Ahlem Lahmar,
  • Luca Campo,
  • Sihem Mebarki,
  • Sandrine Bichet,
  • Daniel Hess,
  • Martin Degen,
  • Nidhameddine Kchir,
  • Nidhameddine Kchir,
  • Leila Charrada-Ben Farhat,
  • Leila Charrada-Ben Farhat,
  • Rania Hefaiedh,
  • Christian Ruiz,
  • Luigi M. Terracciano,
  • Richard P. Tucker,
  • Lotfi Hendaoui,
  • Lotfi Hendaoui,
  • Ruth Chiquet-Ehrismann,
  • Ruth Chiquet-Ehrismann

DOI
https://doi.org/10.3389/fimmu.2020.630139
Journal volume & issue
Vol. 11

Abstract

Read online

Extrahepatic cancers of the biliary system are typically asymptomatic until after metastasis, which contributes to their poor prognosis. Here we examined intrahepatic cholangiocarcinomas (n = 8), carcinomas of perihilar bile ducts (n = 7), carcinomas of the gallbladder (n = 11) and hepatic metastasis from carcinomas of the gallbladder (n = 4) for the expression of the extracellular matrix glycoproteins tenascin-C and tenascin-W. Anti-tenascin-C and anti-tenascin-W immunoreactivity was found in all biliary tract tumors examined. Unlike tenascin-C, tenascin-W was not detected in normal hepatobiliary tissue. Tenascin-W was also expressed by the cholangiocarcinoma-derived cell line Huh-28. However, co-culture of Huh-28 cells with immortalized bone marrow-derived stromal cells was necessary for the formation and organization of tenascin-W fibrils in vitro. Our results indicate that tenascin-W may be a novel marker of hepatobiliary tumor stroma, and its absence from many normal tissues suggests that it may be a potential target for biotherapies.

Keywords